{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:10Z","timestamp":1793090290731,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105578","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:20:17Z","timestamp":1788452417000},"page":"105578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Late-onset immune checkpoint inhibitor-associated myocarditis: A systematic review and patient-level synthesis"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-6975","authenticated-orcid":false,"given":"Priyanth","family":"Alaguraja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1255-873X","authenticated-orcid":false,"given":"Eyad Mohammed","family":"Eldesouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-914X","authenticated-orcid":false,"given":"Saeed","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiqullah","family":"Sadaqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-7476","authenticated-orcid":false,"given":"Ibrahim","family":"Antoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105578_bib1","article-title":"Delayed-onset ICI-associated myocarditis","volume":"30","author":"Adel","year":"2025","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib2","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/S0735-1097(20)33900-0","article-title":"Very late presentation of fulminant myocardial immune-related toxicity in a patient on pembrolizumab","volume":"75","author":"Ali","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/acr-2025-147","article-title":"Pembrolizumab-induced nonischemic cardiomyopathy: a case report of a rare immune-related adverse event","volume":"9","author":"Bahar","year":"2025","journal-title":"AME Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2024.101787","article-title":"Atypical presentation of myocarditis: underrecognized complication of immune checkpoint inhibitors","volume":"27","author":"Beauchamp","year":"2025","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.critrevonc.2026.105578_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI features and prognostic value in immune checkpoint inhibitor\u2013induced myocarditis","volume":"303","author":"Cadour","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2026.105578_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105578_bib7","first-page":"44","article-title":"The toxic tango: TKI and ICI cardiotoxicities","volume":"9","author":"Del Cid Fratti","year":"2023","journal-title":"Cardio-Oncol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ph16040625","article-title":"Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors: a prospective multicenter study","volume":"16","author":"Delombaerde","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2026.105578_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105578_bib10","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0735-1097(21)03257-5","article-title":"Pericarditis with associated pericardial effusion and a possible myocarditis two years after a single dose of durvalumab for treatment of lung cancer","volume":"77","author":"Eromosele","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib11","article-title":"Immune-related adverse event-myocarditis with marked ST-segment elevation requiring differentiation from COVID-19-induced myocarditis: a case report","volume":"8","author":"Fujita","year":"2024","journal-title":"Eur. Heart J. - Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib12","article-title":"Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate","volume":"3","author":"Gallegos","year":"2019","journal-title":"Eur. Heart J. - Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","article-title":"Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton\u2019s Tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance","volume":"87","author":"Ganatra","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.critrevonc.2026.105578_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.critrevonc.2026.105578_bib15","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1182\/blood-2023-190513","article-title":"Safety and efficacy of immune checkpoint inhibitors in the treatment of hodgkin lymphoma in people living with human immunodeficiency virus: a case series","volume":"142","author":"Graeter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105578_bib16","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"10.1016\/j.critrevonc.2026.105578_bib17","article-title":"Left ventricular dysfunction caused by combined pembrolizumab and lenvatinib following doxorubicin","volume":"30","author":"Ishikawa","year":"2025","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.critrevonc.2026.105578_bib19","article-title":"Refractory ventricular arrhythmia in a patient with suspected immune checkpoint inhibitor-related myocarditis: a case report","volume":"9","author":"Jin","year":"2025","journal-title":"Eur. Heart J. - Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib20","first-page":"1703","volume":"41","author":"Jiping","year":"2021","journal-title":"A Case Report. Recurr. Metastatic Tongue Squamous Cell. Carcinoma Treat. Salvage Surg. Comb. Chemoradiotherapy Seq. Immune Checkp. Inhib."},{"key":"10.1016\/j.critrevonc.2026.105578_bib21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105578_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.14059","article-title":"Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience","author":"Kitano","year":"2024","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib23","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.953001","article-title":"A 79-Year-Old Woman With Stage IIIB Lung Squamous Cell Carcinoma Presenting With Late-Onset Durvalumab\u2011Associated Myocarditis Requiring Differentiation From Pericardial Invasion","volume":"27","author":"Kodaka","year":"2026","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31486\/toj.25.0063","article-title":"Immune checkpoint inhibitor\u2013induced myocarditis: a late presentation","volume":"26","author":"Koos","year":"2026","journal-title":"Ochsner J."},{"key":"10.1016\/j.critrevonc.2026.105578_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1328378","article-title":"Case Report: Sudden very late-onset near fatal PD1 inhibitor-associated myocarditis with out-of-hospital cardiac arrest after >2.5 years of pembrolizumab treatment","volume":"11","author":"Lewis","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.critrevonc.2026.105578_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1832047","article-title":"Case Report: Two cases of PD-1 inhibitor\u2013associated myocarditis with bidirectional ventricular tachycardia","volume":"17","author":"Lian","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases","volume":"27","author":"Liu","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2026.105578_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.7644-21","article-title":"Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy","volume":"61","author":"Maetani","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105578_bib29","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib30","article-title":"Smoldering Myocarditis Unmasked by Pembrolizumab-Induced Myositis","volume":"30","author":"Mark","year":"2025","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105578_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaccao.2026.07.008","article-title":"Inflammatory cell profiles in early- and late-manifestation immune checkpoint inhibitor myocarditis","author":"Maruyama","year":"2026","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.critrevonc.2026.105578_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70536","article-title":"Refining the treatment of immune checkpoint inhibitor\u2013associated myocarditis: challenges, innovations and rechallenge considerations","author":"Mincu","year":"2026","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib33","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2169\/internalmedicine.9161-21","article-title":"An autopsy case of late-onset fulminant myocarditis induced by nivolumab in gastric cancer","volume":"61","author":"Naganuma","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.critrevonc.2026.105578_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaccao.2022.04.007","article-title":"Late-onset immunotherapy-induced myocarditis 2 years after checkpoint inhibitor initiation","volume":"4","author":"Nguyen","year":"2022","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.critrevonc.2026.105578_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cjco.2022.03.007","article-title":"A case of lung cancer with very-late-onset immune checkpoint inhibitor-related myocarditis","volume":"4","author":"Nishikawa","year":"2022","journal-title":"CJC Open."},{"key":"10.1016\/j.critrevonc.2026.105578_bib36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105578_bib37","unstructured":"Sahu, V., 2026. Critiplot: A Critical Appraisal Plot Visualiser for Risk of Bias in Systematic Reviews and Meta-Analyses. https:\/\/doi.org\/10.5281\/ZENODO.17236600."},{"key":"10.1016\/j.critrevonc.2026.105578_bib38","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5981\/jjhnc.51.19","article-title":"A case report of nasopharyngeal carcinoma with IrAE myocarditis caused by pembrolizumab administration","volume":"51","author":"Shiratori","year":"2025","journal-title":"Toukeibu Gan"},{"key":"10.1016\/j.critrevonc.2026.105578_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13410-025-01473-2","article-title":"Type 1 diabetes complicated by immune myocarditis induced by toripalimab: a case report","volume":"46","author":"Shuiqing","year":"2026","journal-title":"Int. J. Diabetes Dev. Ctries."},{"key":"10.1016\/j.critrevonc.2026.105578_bib41","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/S0735-1097(20)33537-3","article-title":"Keeping immune checkpoint inhibitor myocarditis in check: simultaneous venoarterial ecmo and impella support as a bridge to recovery","volume":"75","author":"Stein-Merlob","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib42","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.critrevonc.2026.105578_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cardfail.2024.10.264","article-title":"Late-onset pembrolizumab induced immune checkpoint mediated myocarditis","volume":"31","author":"Urioste","year":"2025","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.critrevonc.2026.105578_bib44","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/S0735-1097(22)03643-9","article-title":"Double jeopardy: an unusual case of delayed myocarditis following ICI-associated dermatopathy","volume":"79","author":"Vance","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/10781552251349459","article-title":"Evaluating patients on immune checkpoint inhibitors for cardiac adverse events: The EPICC study","author":"Vang","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2026.105578_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12872-025-04764-y","article-title":"Pacing therapy for immune checkpoint inhibitors-associated atrioventricular block: a single-center cohort study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.critrevonc.2026.105578_bib47","first-page":"812.e1","article-title":"Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.critrevonc.2026.105578_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102997","article-title":"Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial","volume":"79","author":"Yu","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:56:07Z","timestamp":1793087767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"alternative-id":["S1040842826004658"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105578","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late-onset immune checkpoint inhibitor-associated myocarditis: A systematic review and patient-level synthesis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105578"}}